IMRX vs PRTA vs ARQT vs RCUS vs IMVT

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Immuneering Corporation (IMRX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -82. 7% for Prothena Corporation plc (PRTA). Over 10 years, the gap is even starker: IMVT returned +237. 9% versus PRTA's -82. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Immuneering Corporation (IMRX) is the lower-risk stock at 1.

33β versus Arcus Biosciences, Inc. 's 2. 00β — meaning RCUS is approximately 51% more volatile than IMRX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Immuneering Corporation (IMRX) is the more profitable company, earning 0.

0% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMRX leads at 0. 0% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Arcutis Biotherapeutics, Inc.

(ARQT) trades at 122. 5x forward P/E versus 176. 7x for Prothena Corporation plc — 54. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IMRX: 186. 4% to $12. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Immuneering Corporation (IMRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Arcus Biosciences, Inc. (RCUS) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMRX: -76. 2%, RCUS: +40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IMRX is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.